Academic Bibliography

 Search 200 years of publications by Ghent University researchers.
Advanced search
Add to list
  1. Search results
  2. Impact of SARS-CoV-2 vaccination and ...

Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post CD19-CAR-T : an EPICOVIDEHA survey

Jaap A. van Doesum, Jon Salmanton-García, Francesco Marchesi, Roberta Di Blasi, Iker Falces-Romero, Alba Cabirta, Francesca Farina, Caroline Besson, Barbora Weinbergerová, Jens Van Praet (UGent) , et al.
(2023) BLOOD ADVANCES. 7(11). p.2645-2655
Author
Organization
Abstract
Patients with previous CD19 directed chimeric antigen receptor T cell therapy (CAR T)-cell therapy have a prolonged vulnerability to viral infections. Coronavirus diseases 2019 (COVID-19) has a great impact and has previously been shown to cause high mortality in this population. Until now, real world data of the impact of vaccination and treatment on patients with COVID-19 after CD19 directed CAR T-cell therapy are lacking. Therefore, this multicenter retrospective study was conducted with data from the EPICOVIDEHA survey. Sixty-four patients were identified. The overall mortality caused by COVID-19 was 31%. Patients infected with the Omicron variant had a significantly lower risk of death due to COVID-19 compared to patients infected with previous variants (7% versus 58% (P=0.012)). Twenty-six patients were vaccinated at time of COVID-19 diagnosis. Two vaccinations showed marked but unsignificant reduction risk of COVID-19 caused mortality (33.3% versus 14.2% (P=0.379)).Also the course of disease appears milder with less frequent ICU admissions (39% versus 14% (P=0.054)) and shorter duration of hospitalization (7 versus 27.5 days (P=0.022)). Of the available treatment options, only monoclonal antibodies seemed to be effectively reducing mortality from 32% to zero (P=0.036). We conclude that survival rates of CAR T-cell recipients with COVID-19 improved over time and that the combination of prior vaccination and monoclonal antibody treatment significantly reduces their risk of death.
Keywords
Hematology

Citation

Please use this url to cite or link to this publication:

MLA
van Doesum, Jaap A., et al. “Impact of SARS-CoV-2 Vaccination and Monoclonal Antibodies on Outcome Post CD19-CAR-T : An EPICOVIDEHA Survey.” BLOOD ADVANCES, vol. 7, no. 11, 2023, pp. 2645–55, doi:10.1182/bloodadvances.2022009578.
APA
van Doesum, J. A., Salmanton-García, J., Marchesi, F., Di Blasi, R., Falces-Romero, I., Cabirta, A., … Pagano, L. (2023). Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post CD19-CAR-T : an EPICOVIDEHA survey. BLOOD ADVANCES, 7(11), 2645–2655. https://doi.org/10.1182/bloodadvances.2022009578
Chicago author-date
Doesum, Jaap A. van, Jon Salmanton-García, Francesco Marchesi, Roberta Di Blasi, Iker Falces-Romero, Alba Cabirta, Francesca Farina, et al. 2023. “Impact of SARS-CoV-2 Vaccination and Monoclonal Antibodies on Outcome Post CD19-CAR-T : An EPICOVIDEHA Survey.” BLOOD ADVANCES 7 (11): 2645–55. https://doi.org/10.1182/bloodadvances.2022009578.
Chicago author-date (all authors)
van Doesum, Jaap A., Jon Salmanton-García, Francesco Marchesi, Roberta Di Blasi, Iker Falces-Romero, Alba Cabirta, Francesca Farina, Caroline Besson, Barbora Weinbergerová, Jens Van Praet, Martin Schönlein, Alberto Lopez-Garcia, Sylvain Lamure, Anna Guidetti, Cristina De Ramón-Sánchez, Josip Batinic, Eleni Gavriilaki, Athanasios Tragiannidis, Maria Chiara Tisi, Gaëtan Plantefeve, Verena Petzer, Irati Ormazabal-Velez, Joyce Marques de Almeida, Monia Marchetti, Johan A. Maertens, Marina Machado, Austin G Kulasekararaj, José Ángel Hernández-Rivas, Maria Gomes da Silva, Noemí Fernández, Ildefonso Espigado, Lubos Drgona, Giulia Dragonetti, Elisabetta Metafuni, Maria Calbacho, Ola Blennow, Dominik Wolf, Bjorn van Anrooij, Raquel Nunes Rodrigues, Anna Nordlander, Juan-Alberto MARTÍN-GONZÁLEZ, Raphaël Lievin, Moraima Jiménez, Stefanie K Grafe, Ramon Garcia-Sanz, Raúl Córdoba, Laman Rahimli, Tom van Meerten, Oliver A Cornely, and Livio Pagano. 2023. “Impact of SARS-CoV-2 Vaccination and Monoclonal Antibodies on Outcome Post CD19-CAR-T : An EPICOVIDEHA Survey.” BLOOD ADVANCES 7 (11): 2645–2655. doi:10.1182/bloodadvances.2022009578.
Vancouver
1.
van Doesum JA, Salmanton-García J, Marchesi F, Di Blasi R, Falces-Romero I, Cabirta A, et al. Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post CD19-CAR-T : an EPICOVIDEHA survey. BLOOD ADVANCES. 2023;7(11):2645–55.
IEEE
[1]
J. A. van Doesum et al., “Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post CD19-CAR-T : an EPICOVIDEHA survey,” BLOOD ADVANCES, vol. 7, no. 11, pp. 2645–2655, 2023.
@article{01GY2H6H3WH563MR063PBSRYFK,
  abstract     = {{Patients with previous CD19 directed chimeric antigen receptor T cell therapy (CAR T)-cell therapy have a prolonged vulnerability to viral infections. Coronavirus diseases 2019 (COVID-19) has a great impact and has previously been shown to cause high mortality in this population. Until now, real world data of the impact of vaccination and treatment on patients with COVID-19 after CD19 directed CAR T-cell therapy are lacking. Therefore, this multicenter retrospective study was conducted with data from the EPICOVIDEHA survey. Sixty-four patients were identified. The overall mortality caused by COVID-19 was 31%. Patients infected with the Omicron variant had a significantly lower risk of death due to COVID-19 compared to patients infected with previous variants (7% versus 58% (P=0.012)). Twenty-six patients were vaccinated at time of COVID-19 diagnosis. Two vaccinations showed marked but unsignificant reduction risk of COVID-19 caused mortality (33.3% versus 14.2% (P=0.379)).Also the course of disease appears milder with less frequent ICU admissions (39% versus 14% (P=0.054)) and shorter duration of hospitalization (7 versus 27.5 days (P=0.022)). Of the available treatment options, only monoclonal antibodies seemed to be effectively reducing mortality from 32% to zero (P=0.036). We conclude that survival rates of CAR T-cell recipients with COVID-19 improved over time and that the combination of prior vaccination and monoclonal antibody treatment significantly reduces their risk of death.}},
  author       = {{van Doesum, Jaap A. and Salmanton-García, Jon and Marchesi, Francesco and Di Blasi, Roberta and Falces-Romero, Iker and Cabirta, Alba and Farina, Francesca and Besson, Caroline and Weinbergerová, Barbora and Van Praet, Jens and Schönlein, Martin and Lopez-Garcia, Alberto and Lamure, Sylvain and Guidetti, Anna and De Ramón-Sánchez, Cristina and Batinic, Josip and Gavriilaki, Eleni and Tragiannidis, Athanasios and Tisi, Maria Chiara and Plantefeve, Gaëtan and Petzer, Verena and Ormazabal-Velez, Irati and Marques de Almeida, Joyce and Marchetti, Monia and Maertens, Johan A. and Machado, Marina and Kulasekararaj, Austin G and Hernández-Rivas, José Ángel and Gomes da Silva, Maria and Fernández, Noemí and Espigado, Ildefonso and Drgona, Lubos and Dragonetti, Giulia and Metafuni, Elisabetta and Calbacho, Maria and Blennow, Ola and Wolf, Dominik and van Anrooij, Bjorn and Nunes Rodrigues, Raquel and Nordlander, Anna and MARTÍN-GONZÁLEZ, Juan-Alberto and Lievin, Raphaël and Jiménez, Moraima and Grafe, Stefanie K and Garcia-Sanz, Ramon and Córdoba, Raúl and Rahimli, Laman and van Meerten, Tom and Cornely, Oliver A and Pagano, Livio}},
  issn         = {{2473-9529}},
  journal      = {{BLOOD ADVANCES}},
  keywords     = {{Hematology}},
  language     = {{eng}},
  number       = {{11}},
  pages        = {{2645--2655}},
  title        = {{Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post CD19-CAR-T : an EPICOVIDEHA survey}},
  url          = {{http://doi.org/10.1182/bloodadvances.2022009578}},
  volume       = {{7}},
  year         = {{2023}},
}
Altmetric
View in Altmetric
Web of Science
Times cited: